We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox and Bosch Healthcare Alliance Targets COVID-19 Testing

By LabMedica International staff writers
Posted on 28 Oct 2020
Print article
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)
A partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) aims to alter the testing landscape in both laboratory and non-laboratory settings toward the rapid detection of COVID-19.

The collaborative approach of Randox and Bosch Healthcare focuses on safety precautions as well as solutions to both analyzing and differentiating COVID-19 from other viral respiratory diseases. Their combined efforts have resulted in the launch of the Vivalytic, an all-in-one solution for molecular diagnostics, consolidating nucleic acid extraction, polymerase chain reaction (PCR) and detection on a single platform.

The Viral Respiratory Infection array (VRI) rapidly detects the SARS-CoV-2 virus that causes COVID-19 while simultaneously differentiating between nine other respiratory diseases, in less than two and a half hours. Randox, Bosch Healthcare and R-Biopharm also offer various analysis strategies to detect SARS-CoV-2. Capable of providing reliable results in just 39 minutes, with a sensitivity of 98% and specificity of 100%, the Vivalytic SARS-CoV-2 rapid test is currently among the fastest PCR tests worldwide.

Randox and Bosch Healthcare offer a range of testing strategies, including the upcoming SARS-CoV-2 Pooling test. The SARS-CoV-2 Pooling test is a rapid solution for the detection of SARS-CoV-2, offering an accelerated decentralized testing approach for effectively and efficiently monitoring and detecting viral infection from the onset. The solution is capable of detecting SARS-CoV-2 from up to five pooled samples simultaneously with a capacity for processing more than 160 patient samples a day. Sample pooling allows more people to be tested quickly using fewer testing resources. The pooling can be done at the level of a ward, medical specialty, social bubble, or a group of colleagues. It also has potential for use in other settings, such as pre-operative screening, schools & universities, prisons, nursing homes, primary care, and large workplaces.
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Sekisui Diagnostics UK Ltd.